Brain disease

#AbbVie #Brain disease #Collaboration #Nxera Pharma

Nxera Pharma receives $10 million from collaboration with AbbVie

Nxera Pharma has received $10 million from pharmaceutical company AbbVie under the terms of the multi-target discovery collaboration on neurological diseases, Nxera has announced.  Nxera and AbbVie entered the multi-target collaboration in 2022, leveraging Nxera’s NxWave platform to discover novel medicines targeting G protein-coupled receptors (GPCRs) associated with neurological disease. Read More

#Business & Investment #News

#Brain disease #Johnson & Johnson #Neurology #Neuroscience

Shaping the future of neuroscience

Berkin Gökbudak, Senior Director of Commercial Strategy for Neuroscience, Pulmonary Hypertension & Cardiovascular & Metabolism, at Johnson & Johnson, looks towards neuroscience strategies that can help advance treatments for brain disorders. The human brain is the last, and greatest, scientific frontier – it’s been described as the most complex structure… Read More

#Exclusive Content

Neuroscience innovation
#AI #Alzheimer's #Artificial intelligence (AI) #Biomarkers #Brain disease #Drug discovery #Inherited tauopathies #Mental health #Nervous system disorders #Neurodegenerative disorders #Neurology #Neuroscience #Neurotechnology #Psychiatry #Tau protein

New podcast on innovation in neuroscience

This is the latest episode of the free DDW narrated podcast, titled “Where is the latest innovation in neuroscience?” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: Taking a new approach to tackle neurodegenerative diseases,… Read More

#News

Brain Awareness Week
#Brain #Brain Awareness Week #Brain disease #Dementia #Drug discovery #Parkinson's #Stroke

Brain Awareness Week: the wonders of brain science

DDW’s Diana Spencer reviews some of the advances in drug discovery for diseases of the brain in the last month. Brain Awareness Week is an annual global campaign that takes place from March 13-19, aimed at raising awareness and support for brain science and issues related to the brain and… Read More

#Exclusive Content

Cancer cells
#Brain disease #Cancer research #Cell and gene therapy #CRISPR #CRISPR-Cas9 #Gene editing #Mouse models #Neuroscience #Oncology

Scientists turn cancer cells into anticancer agents

Harvard investigators have developed a new cell therapy approach to eliminate established tumours and induce long-term immunity.   In this early research, Khalid Shah, Professor of Neurosurgery at Harvard Medical School and Brigham and Women’s Hospital, and colleagues tested the vaccine in an advanced mouse model of brain… Read More

#Cancer Research #News #Trending News

Brain inflammation
#Alzheimer's #Brain disease #Neurodegenerative disorders #Neuroinflammation #Neurology #Parkinson's

Covid-19 triggers inflammation in the brain

Research led by The University of Queensland has found that Covid-19 activates the same inflammatory response in the brain as Parkinson’s disease.  The discovery identified a potential future risk for neurodegenerative conditions in people who have had Covid-19, but also a possible treatment.  The UQ… Read More

#Covid-19 #News

#AI #Artificial intelligence (AI) #Brain disease #Nervous system disorders #Neuroscience #Neurotechnology

Keeping technology at the front of neuroscience research 

Listen to this article on the DDW Podcast: David Gray, CSO of Inscopix talks to Lu Rahman about the company’s understanding of the neuroscience market and its quest to improve technologies for neuroscientists to enable multimodal research.  Inscopix is a neurotechnology company focused on understanding the function of the brain to… Read More

#Exclusive Content

#Brain disease #Cancer #Oncology #Small molecules #Therapeutics #Tumours

Hemispherian’s epigenetic therapeutics act on a new mechanism of action

Hemispherian is a Norwegian pharmaceutical company focused on developing a novel class of small molecule drugs (GLIX) that target the TET2 enzyme. Lu Rahman spoke to Zeno Albisser, CEO, to find out more about the company’s expertise.  LR: What it does Hemispherian do?  ZA: We are focused on developing a novel class of small molecule drugs (GLIX)… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Alzheimer's #Brain disease #Drug targets #Schizophrenia

Research reveals drug targets for memory enhancement  

Bristol-led research has identified specific drug targets within the neural circuits that encode memories, paving the way for significant advances in the treatment of a broad spectrum of brain disorders.  Loss of memory is a core feature of many neurological and psychiatric disorders including Alzheimer’s disease and… Read More

#News

#Brain disease #Drug development #Drug discovery #Screening

Human cerebral organoid used to test drug for fatal brain disease

After establishing a human cerebral organoid system to study Creutzfeldt-Jakob disease (CJD), National Institutes of Health researchers have further developed the model to screen drugs for potential CJD treatment. CJD, a fatal neurodegenerative brain disease of humans caused by infectious prion proteins, affects about 1 in a million people annually. Read More

#News